Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INMD 
InMode Ltd (INMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: INMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.25
1 Year Target Price $16.25
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 943.08M USD | Price to earnings Ratio 6.27 | 1Y Target Price 16.25 |
Price to earnings Ratio 6.27 | 1Y Target Price 16.25 | ||
Volume (30-day avg) 7 | Beta 1.93 | 52 Weeks Range 13.14 - 19.85 | Updated Date 08/28/2025 |
52 Weeks Range 13.14 - 19.85 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate 0.41 | Actual 0.47 |
Profitability
Profit Margin 44.5% | Operating Margin (TTM) 23.93% |
Management Effectiveness
Return on Assets (TTM) 9.14% | Return on Equity (TTM) 25.91% |
Valuation
Trailing PE 6.27 | Forward PE 9.63 | Enterprise Value 455567018 | Price to Sales(TTM) 2.35 |
Enterprise Value 455567018 | Price to Sales(TTM) 2.35 | ||
Enterprise Value to Revenue 1.13 | Enterprise Value to EBITDA 3.95 | Shares Outstanding 63209200 | Shares Floating 53530168 |
Shares Outstanding 63209200 | Shares Floating 53530168 | ||
Percent Insiders 15.35 | Percent Institutions 59.23 |
Upturn AI SWOT
InMode Ltd
Company Overview
History and Background
InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel. It develops, manufactures, and markets energy-based aesthetic and surgical platforms. The company has focused on minimally invasive and non-invasive procedures and has expanded its global presence through strategic acquisitions and partnerships.
Core Business Areas
- Surgical Solutions: Develops and provides minimally invasive surgical aesthetic solutions using radiofrequency (RF) technology.
- Aesthetic Solutions: Offers non-invasive and minimally invasive aesthetic solutions utilizing RF, laser, and intense pulsed light (IPL) technologies.
Leadership and Structure
The leadership team includes Moshe Mizrahy (Chairman and CEO), Shakil Amir (President, North America), and Yair Malca (CFO). The company operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- Morpheus8: A fractional RF microneedling device for skin resurfacing, tightening, and wrinkle reduction. Competitors include Cutera's Secret RF and Endymed's Intensif. Revenue contribution is significant but precise market share is difficult to determine. The global microneedling market is highly competitive.
- Evolve: A hands-free platform for non-invasive body contouring. The system delivers RF energy and EMS (electrical muscle stimulation) to remodel skin, treat adipose tissue, and tone muscles. Competitors include CoolSculpting (Zeltiq Aesthetics - now part of Allergan, ABBV) and Emsculpt Neo (BTL Industries). Market share data is proprietary, and varies based on product line and geographical region.
- BodyTite: A minimally invasive body contouring and liposuction solution. It uses RFAL (Radio-Frequency Assisted Lipolysis) technology. Competitors include VASERlipo (Solta Medical, Bausch Health) and Smartlipo (Cynosure). Market Share is difficult to determine as it is based on how much of the market of liposuction products it can take.
Market Dynamics
Industry Overview
The medical aesthetics market is experiencing substantial growth, driven by an aging population, increasing disposable incomes, and a rising awareness of aesthetic procedures. The market is competitive, with numerous companies offering various energy-based solutions.
Positioning
InMode Ltd. is positioned as a provider of innovative, minimally invasive and non-invasive aesthetic solutions, catering to both surgeons and aesthetic practitioners. Competitive advantages include proprietary RF technologies and a focus on clinical outcomes.
Total Addressable Market (TAM)
The TAM for medical aesthetics is expected to reach hundreds of billions of USD by the end of the decade. InMode is positioned well to capture a share of this market due to its innovative technologies and strong branding.
Upturn SWOT Analysis
Strengths
- Proprietary RF technologies
- Strong brand recognition
- Focus on clinical outcomes
- Global distribution network
- Experienced management team
Weaknesses
- Concentration of revenue in specific products
- Reliance on third-party distributors in some regions
- Potential for increased competition
- High R&D expenditure
Opportunities
- Expansion into new geographic markets
- Development of new aesthetic and surgical applications
- Strategic acquisitions of complementary technologies
- Partnerships with leading medical institutions
Threats
- Increased competition from established players
- Technological obsolescence
- Changes in regulatory requirements
- Economic downturns impacting consumer spending
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- ALGN
- ZBH
- CUTERA
Competitive Landscape
InMode faces competition from both established players and smaller companies offering similar technologies. InMode differentiates itself through its innovative RF technologies, clinical outcomes, and brand recognition. ALGN and ZBH are leading the market share.
Major Acquisitions
None
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: None
Growth Trajectory and Initiatives
Historical Growth: InMode has experienced significant revenue growth over the past years, driven by increased adoption of its products and expansion into new markets.
Future Projections: Analyst estimates vary, but the consensus is for continued revenue growth, driven by innovation and market expansion. See financial news sources for specifics.
Recent Initiatives: Recent initiatives include expanding its product portfolio, entering new geographic markets, and strengthening its relationships with key opinion leaders.
Summary
InMode is a strong company with innovative RF technologies and a growing presence in the medical aesthetics market. Its financial performance is solid, and its growth trajectory is positive. However, it faces competition from established players and needs to manage its reliance on specific products and geographic regions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- InMode Ltd. Investor Relations
- SEC Filings
- Industry Reports (e.g., Mordor Intelligence, Grand View Research)
- Analyst Reports (e.g., TipRanks, Yahoo Finance)
- Company comparison websites (e.g., Craft.co)
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share data and TAM estimates are based on available information and may vary. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMode Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-08-08 | Co-Founder, CEO & Director Mr. Moshe Mizrahy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 599 | Website https://www.inmodemd.com |
Full time employees 599 | Website https://www.inmodemd.com | ||
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.